Cargando…
Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines.
Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968845/ https://www.ncbi.nlm.nih.gov/pubmed/8123477 |
_version_ | 1782134829257588736 |
---|---|
author | Rantanen, V. Grénman, S. Kulmala, J. Grénman, R. |
author_facet | Rantanen, V. Grénman, S. Kulmala, J. Grénman, R. |
author_sort | Rantanen, V. |
collection | PubMed |
description | Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosensitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an IC50 value, the drug concentration causing 50% inhibition of clonogenic survival. IC50 values were obtained from dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(alpha D + beta D2)]. The IC50 values of the two platinum derivatives varied considerably. The values for cisplatin varied between 0.022 microgram ml-1 and 0.56 microgram ml-1 and the corresponding values for carboplatin were 0.096-1.20 microgram ml-1. The range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow. However, no constant ratio between carboplatin IC50 and cisplatin IC50 could be detected. The equivalent doses with regard to efficacy of these two platinum analogues remain to be determined. |
format | Text |
id | pubmed-1968845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1994 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19688452009-09-10 Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Rantanen, V. Grénman, S. Kulmala, J. Grénman, R. Br J Cancer Research Article Platinum analogues are frequently used in the treatment of advanced or recurrent endometrial cancer. To study the sensitivity of endometrial cancer to cisplatin and carboplatin, we tested two long-established (RL95-2, KLE) and six new cell lines (UM-EC-1, UM-EC-2, UM-EC-3, UT-EC-2A, UT-EC-2B, UT-EC-3) using the 96-well-plate clonogenic assay. This assay has proven to be suitable for testing chemosensitivity of both adenocarcinoma and squamous cell carcinoma. The chemosensitivity was expressed as an IC50 value, the drug concentration causing 50% inhibition of clonogenic survival. IC50 values were obtained from dose-response curves after fitting the data by the linear quadratic equation, F = exp[-(alpha D + beta D2)]. The IC50 values of the two platinum derivatives varied considerably. The values for cisplatin varied between 0.022 microgram ml-1 and 0.56 microgram ml-1 and the corresponding values for carboplatin were 0.096-1.20 microgram ml-1. The range of the ratios between carboplatin IC50 and cisplatin IC50, from 1.5:1 to 4.4:1, was rather narrow. However, no constant ratio between carboplatin IC50 and cisplatin IC50 could be detected. The equivalent doses with regard to efficacy of these two platinum analogues remain to be determined. Nature Publishing Group 1994-03 /pmc/articles/PMC1968845/ /pubmed/8123477 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Rantanen, V. Grénman, S. Kulmala, J. Grénman, R. Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title | Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title_full | Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title_fullStr | Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title_full_unstemmed | Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title_short | Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
title_sort | comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968845/ https://www.ncbi.nlm.nih.gov/pubmed/8123477 |
work_keys_str_mv | AT rantanenv comparativeevaluationofcisplatinandcarboplatinsensitivityinendometrialadenocarcinomacelllines AT grenmans comparativeevaluationofcisplatinandcarboplatinsensitivityinendometrialadenocarcinomacelllines AT kulmalaj comparativeevaluationofcisplatinandcarboplatinsensitivityinendometrialadenocarcinomacelllines AT grenmanr comparativeevaluationofcisplatinandcarboplatinsensitivityinendometrialadenocarcinomacelllines |